Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Exosome complex component RRP40 (EXOSC3) is a non-catalytic structural subunit of the RNA exosome, a highly conserved multi-protein complex responsible for the processing, maturation, and degradation of many types of cellular RNA, including rRNA, snRNA, snoRNA, mRNA, and non-coding RNAs[2][3][4]. EXOSC3 is essential for normal development, particularly of the brain’s cerebellum and spinal cord motor neurons, and loss-of-function mutations cause rare, severe neurodevelopmental diseases such as pontocerebellar hypoplasia type 1B (PCH1B)[1][2][5]. EXOSC3 lacks catalytic activity itself but is required for the structural stability and correct assembly of the exosome complex, and thus is vital for cellular RNA homeostasis[3][4][5]. There are no known direct therapeutic drugs targeting EXOSC3, nor established companion biomarkers or mechanisms of drug action; rather, its dysfunction is directly associated with monogenic, developmental neurodegeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Exosome complex component RRP40 (EXOSC3).